ZymoGenetics Snags $70M Payout From BMS For Phase II Start Of New Interferon
This article was originally published in The Pink Sheet Daily
Executive Summary
A trial will evaluate PEG-Interferon lambda - a drug Bristol includes among its "string of pearls" - versus Pegasys for the treatment of hepatitis C.